Skip to main content

Table 2 Selected studies presentation for fluoxetine

From: Duloxetine compared with fluoxetine and venlafaxine: use of meta-regression analysis for indirect comparisons

Study Inclusion criteria Age Percent male Duration (weeks) Treatment Dosage (mg/day) Patients per arm Effect size (SD) Response (%) Dropout (%)
Fabre et al. [15] Age 21–70
HAM-D ≥ 20
   5 Fluoxetine
Placebo
40–80 22
26
-0.8 (0.1)   0.50
0.44
Stark et al. [16] DSM-III, Age 18–70
HAM-D21 ≥ 20
40 0.32 6 Fluoxetine
Placebo
20–80 185
169
-0.3(0.01) 0.63
0.38
0.37
0.45
Cohn et al. [17] DSM-III, Age 20–64
HAM-D ≥ 20
41 0.40 6 Fluoxetine
Placebo
20–80 54
57
-1.3(0.04) 0.72
0.30
0.30
0.72
Fieve et al. [18] DSM-III, Age 18–65
HAM-D21 ≥ 20
  0.57 6 Fluoxetine
Fluoxetine
Fluoxetine
Placebo
5
20
40
14
13
13
9
-0.5 (0.1)   
Rickels et al. [19] DSM-III, Age 21–70
HAM-D ≥ 20
47.2 0.21 5 Fluoxetine
Placebo
20–80 18
24
-0.7 (0.2) 0.90
0.39
 
Goodnick et al. [20] DSM-III, Age 18–65
HAM-D ≥ 116
  0.54 7 Fluoxetine
Placebo
20–60 30
5
-1.1(0.3)
0.1(0.2)
  
Wernicke et al. [21] DSM-III, Age 18–65
HAM-D ≥ 20
39.8 0.43 6 Fluoxetine
Fluoxetine
Fluoxetine
Placebo
20
40
60
97
97
103
48
-0.5(0.03)
-0.5(0.03)
-0.2(0.03)
0.53
0.61
0.48
0.27
0.38
0.40
0.55
0.44
Fabre et al. [22] DSM-III, Age 18–65
HAM-D ≥ 14
   6 Fluoxetine
Fluoxetine
Fluoxetine
Placebo
20
40
60
22
25
25
12
-2.1 (0.4)
-1.5 (0.3)
-2.3 (0.5)
0.67
0.31
1
0
 
Wernicke et al. [23] DSM-III, Age 18–65
HAM-D ≥ 14
39 0.37 6 Fluoxetine
Fluoxetine
Fluoxetine
Placebo
5
20
40
94
91
92
77
-0.5(0.02)
-0.4(0.02)
-0.5(0.02)
0.54
0.64
0.65
0.33
 
Harto et al. [24] DSM-III, Age 18–65
HAM-D ≥ 20
38.4
43.8
36.4
0.37
0.37
0.37
6 Fluoxetine
Fluoxetine
Fluoxetine
Placebo
5
20
40
8
10
9
8
1 (0.3)
1.1 (0.3)
0.9 (0.3)
  
Byerley et al. [25] DSM-III
HAM-D21 ≥ 20
38.9 0.31 6 Fluoxetine
Placebo
40–80 32
29
-1.1 (0.1)   0.38
0.45
Muijen et al. [26] Research Diagnostic Criteria, Age 18–65
HAMD-D17 ≥ 17
35.8 0.37 6 Mianserin
Fluoxetine
Placebo
20
20
27
26
28
-1.2 (0.2) 0.55
0.23
0.46
0.43
Feighner et al. [27] DSM-III, Age 18–70
HAMD-D21 ≥ 20, RSDM ≥ 8 and RSDM ≥ Covi
45 0.26 6 Imipramine
Fluoxetine
Placebo
150
80 (median)
46
51
48
-0.3(0.04)   0.51
0.68
Dunlop et al. [28] DSM-III, Age 18–65
HAMD-D ≥ 14 and RSDM >Covi
39.3
39.3
39.3
  6 Fluoxetine
Fluoxetine
Fluoxetine
Placebo
20
40
60
103
99
97
56
-0.1(0.03)
-0.03 (0.03)
0.1(0.03)
0.53
0.51
0.59
0.36
0.35
0.41
0.39
0.34
Valducci et al. [29] DSM-III-R, Age 19–67
HAMD-D >18
  0.43 8 Fluoxetine
Placebo
20 20
20
-0.9 (0.1) 0.70
0.25
 
Heiligenstein et al. [31] DSM-III-R, Age 18–65
HAMD-D17 ≥ 15
44.4   8 Fluoxetine
Placebo
20 46
43
0.1 (0.1)
-0.9 (0.1)
0.61
0.41
 
Sramek et al. [32] DSM-III-R, Age 18–65
HAMD-D24 ≥ 21 with item 1 ≥ 2, HAM-A ≤ 18, HAMD-D24 <HAM-A, RSDM ≥ 8 and RSDM >Covi
33.9 0.40 9 ABT-200
Fluoxetine
Placebo
160–320
20
72
72
72
-0.3(0.03)   0.17
0.13
Fava et al. [33] DSM-III-R, Age (mean 41,3) HAMD-D17 ≥ 18, Raskin depression score ≥ 8 and superior to Raskin anxiety score 41.3 0.49 12 Paroxetine
Fluoxetine
Placebo
20–50
20–80
55
54
19
0.1 (0.1) 0.57
0.53
 
Rudolph et al. [34] DSM-IV, Age > 18
HAMD-D21 ≥ 20
40 0.33 8 Venlafaxine
XR
Fluoxetine
Placebo
75–225
20–60
100
103
98
-0.2(0.02) 0.50
0.42
0.27
0.21
Coleman et al. [35] DSM-IV, Age 18–76
HAMD-D21 ≥ 20
37.1   8 Bupropion SR
Fluoxetine
Placebo
150–400
20–60
150
154
152
-0.2(0.01) 0.57
0.50
0.37
0.33
Goldstein et al. [9] DSM-IV, Age 18–65
HAMD-D17 ≥ 15 and CGI-S ≥ 4
39.7 0.35 8 Duloxetine
Fluoxetine
Placebo
40–120
20
70
33
70
-0.2(0.04) 0.45
0.39
0.36
0.34
Silverstone et al. [42] DSM-IV, Age ≥ 18
HAMD-D21 ≥ 20 (on the first 17 items), Covi ≥ 8
43.2 0.4 12 Fluoxetine
Venlafaxine
XR
Placebo
20–60
75–225
121
128
119
-0.6(0.02) 0.62
0.43
0.26
0.40
Globally   40 ± 3 0.39 7 ± 2 Fluoxetine
Placebo
20–80 2078
1093
-0.46(0.11) 0.37(0.09) ** -0.02(0.09) **
  1. ** Log Odds ratios (SD)